This research finding should benefit the company’s Colaris test, which identifies genetic mutations in the MLH1, MSH2, MSH6, and PMS2 genes and assesses a person's risk of developing colorectal and ...

You know what’s better than being the first one on your block to know about the next up-and-coming unsigned band so you can say “I can knew them back in the day” when they become huge? Nothing is, ...

SALT LAKE CITY, Nov. 29, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today said results from a major health economics study in Cancer Prevention Research, a journal of the American ...

First-mover advantage is no guarantee of early success. Myriad Genetics, which makes diagnostic tests to detect predisposition to cancers, burned through more than $500 million over 17 years before ...

Myriad Genetics ( MYGN) recently made a presentation at a conference, which concluded that proper diagnostic test for Lynch syndrome, a hereditary form of colon cancer, should include the PMS2 gene.